Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 551 to 575 of 921

TitleReference numberPublishedLast updated
Risankizumab for treating moderate to severe plaque psoriasisTA596
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Letermovir for preventing cytomegalovirus disease after a stem cell transplantTA591
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitisTA590
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activityTA589
Bisphosphonates for treating osteoporosisTA464
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapiesTA171
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormalityTA322
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomibTA586
Lenalidomide plus dexamethasone for previously untreated multiple myelomaTA587
Ocrelizumab for treating primary progressive multiple sclerosisTA585
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetesTA583
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Enzalutamide for hormone-relapsed non-metastatic prostate cancerTA580
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphomaTA577
Certolizumab pegol for treating moderate to severe plaque psoriasisTA574
Tildrakizumab for treating moderate to severe plaque psoriasisTA575
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)TA576
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetesTA572
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)TA570
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Cochlear implants for children and adults with severe to profound deafnessTA566
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemiaTA561

Results per page

  1. 10
  2. 25
  3. 50
  4. All